Xinguang Pharmaceutical released its 2026 interim report. Net profit attributable to the parent in the first half was 39.71 million yuan, up 24.5% year on year. Operating revenue was 143 million yuan, up 1.2% year on year. Net profit attributable to the parent after deducting non-recurring items was 36.21 million yuan, up 23.0% year on year. Net cash flow from operating activities was 57.78 million yuan, up 56.9% year on year. In the second quarter, net profit attributable to the parent was 13.34 million yuan, up 81.2% year on year. The company said it will continue to focus on the research, development, production and sales of proprietary Chinese medicines, chemical drugs and health foods.
Zhejiang Xinguang Pharmaceutical Co LtdFirst-half net profit up 24.5% year on year, beating expectations.
